National Research Corporation EBITDA 2011-2026 | NRC

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA National Research Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
30.2 M	41.2 M	45.9 M	46.7 M	50.6 M	43 M	48.6 M	40.7 M	38.8 M	35.4 M	30.6 M	32.1 M	28.5 M	27.4 M	23.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
50.6 M	23.8 M	37.6 M

Quarterly EBITDA National Research Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9.93 M	3.33 M	10.1 M	-	9.53 M	10.4 M	10.2 M	-	11.5 M	10.9 M	10.4 M	-	12.4 M	12.8 M	13 M	-	13.1 M	12.2 M	12 M	-	13.9 M	10.7 M	12.6 M	-	11.6 M	11.6 M	12.1 M	-	10.6 M	9.08 M	10.2 M	-	8.25 M	9.59 M	11.1 M	-	8.42 M	8.11 M	8.97 M	-	7.62 M	7.39 M	6.84 M	-	8.11 M	7.24 M	9.34 M	-	6.94 M	6.46 M	8.17 M	-	6.8 M	6.43 M	7.32 M	-	5.51 M	5.07 M	6.94 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.9 M	3.33 M	9.44 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Agilent Technologies A	1.67 B	$ 110.24	-2.86 %	$ 33.5 B	USA
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Exagen XGN	-12 M	$ 2.68	-3.94 %	$ 57.8 M	USA
Exact Sciences Corporation EXAS	-81.4 M	-	-	$ 19.8 B	USA
Burning Rock Biotech Limited BNR	-749 M	$ 16.36	-11.57 %	$ 176 M	China
Check-Cap Ltd. CHEK	-25.8 M	-	-	$ 9.42 M	Israel
Koninklijke Philips N.V. PHG	553 M	$ 26.78	-1.33 %	$ 20 B	Niderland
ICON Public Limited Company ICLR	1.59 B	$ 102.08	-0.97 %	$ 8.42 B	Irlanda
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
BioNano Genomics BNGO	-23.8 M	$ 1.16	0.87 %	$ 6.32 M	USA
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
DexCom DXCM	1.16 B	$ 62.25	-5.81 %	$ 24.3 B	USA
Aspira Women's Health AWH	-32.5 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-12.3 M	-	-61.36 %	$ 2.46 M	USA
Biodesix BDSX	-28.7 M	$ 14.21	-2.67 %	$ 1.84 B	USA
Biomerica BMRA	-5.05 M	$ 2.01	-4.74 %	$ 4.62 M	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
Celcuity CELC	-172 M	$ 106.02	-7.66 %	$ 4.96 B	USA
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-518 M	-	0.12 %	$ 80.1 M	China
Castle Biosciences CSTL	24.7 M	$ 23.53	-4.74 %	$ 654 M	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Charles River Laboratories International CRL	428 M	$ 159.16	-3.62 %	$ 7.89 B	USA
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
DarioHealth Corp. DRIO	-36.3 M	$ 8.11	-4.02 %	$ 32.3 M	Israel
Quest Diagnostics Incorporated DGX	2.13 B	$ 195.51	-1.33 %	$ 21.7 B	USA
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
PerkinElmer PKI	762 M	-	-0.91 %	$ 14.7 B	USA
Invitae Corporation NVTA	47.2 M	-	-	$ 21.2 M	USA
Fulgent Genetics FLGT	-49 M	$ 15.59	-4.82 %	$ 471 M	USA
Interpace Biosciences IDXG	8.41 M	$ 1.68	-2.89 %	$ 7.37 M	USA
Guardant Health GH	-398 M	$ 84.61	-3.96 %	$ 10.6 B	USA
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Motus GI Holdings MOTS	-11.5 M	-	-34.28 %	$ 263 K	Israel
IDEXX Laboratories IDXX	1.51 B	$ 558.32	-2.61 %	$ 44.9 B	USA
QIAGEN N.V. QGEN	660 M	-	-	$ 10.6 B	Niderland
Illumina ILMN	-479 M	$ 117.67	-5.41 %	$ 18.7 B	USA
IQVIA Holdings IQV	3.33 B	$ 163.85	-3.28 %	$ 28.2 B	USA
Neogen Corporation NEOG	-942 M	$ 8.7	-4.92 %	$ 1.89 B	USA
Lantheus Holdings LNTH	381 M	$ 74.47	-2.48 %	$ 5.03 B	USA
Medpace Holdings MEDP	562 M	$ 451.2	-3.3 %	$ 13 B	USA
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Mettler-Toledo International MTD	51.1 M	$ 1 232.04	-2.99 %	$ 25.4 B	Schweiz
Myriad Genetics MYGN	-334 M	$ 4.28	-7.36 %	$ 396 M	USA
Laboratory Corporation of America Holdings LH	2.07 B	$ 264.2	-1.56 %	$ 22 B	USA
NeoGenomics NEO	-79.8 M	$ 7.19	-7.35 %	$ 921 M	USA